Hoyle Cohen, LLC Viracta Therapeutics, Inc. Transaction History
Hoyle Cohen, LLC
- $1.31 Billion
- Q2 2024
A detailed history of Hoyle Cohen, LLC transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Hoyle Cohen, LLC holds 14,000 shares of VIRX stock, worth $280. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,000
Previous 14,000
-0.0%
Holding current value
$280
Previous $14,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VIRX
# of Institutions
13Shares Held
467KCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY273KShares$5,4650.0% of portfolio
-
Xtx Topco LTD London, X093.4KShares$1,8670.0% of portfolio
-
United Capital Financial Advisers, LLC Newport Beach, CA43KShares$8590.0% of portfolio
-
Wealth Trust Axiom LLC16.4KShares$3270.0% of portfolio
-
Baader Bank Aktiengesellschaft Unterschleissheim, 2M15.3KShares$3050.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $751K
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...